DLA PIPER LLP (US)

Lobbying for CURRAX PHARMACEUTICALS LLC · Specialty pharmaceutical business

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · Tennessee · House · Senate · $60,000.00 income · posted Apr 21, 2025

Lobbying activity 1

Pharmacy

Legislative and regulatory policies and proposals related to obesity treatment. Article 20 pharmacovigilance proceedings before the European Commission.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.